The unmet need for COVID-19 treatment in immunocompromised patients

BACKGROUND: Immunocompromised (IC) patients are at increased risk of severe and/or prolonged COVID-19. MAIN TEXT: The recent study by Scaglione et al., addresses the issue of IC outpatients with SARS-CoV-2 infection. Authors describe the real-life use of SARS-CoV-2 antivirals and/or monoclonal antib...

Descripción completa

Detalles Bibliográficos
Autores principales: Alessandra, D’Abramo, Serena, Vita, Emanuele, Nicastri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742028/
https://www.ncbi.nlm.nih.gov/pubmed/36503419
http://dx.doi.org/10.1186/s12879-022-07918-x
_version_ 1784848443911438336
author Alessandra, D’Abramo
Serena, Vita
Emanuele, Nicastri
author_facet Alessandra, D’Abramo
Serena, Vita
Emanuele, Nicastri
author_sort Alessandra, D’Abramo
collection PubMed
description BACKGROUND: Immunocompromised (IC) patients are at increased risk of severe and/or prolonged COVID-19. MAIN TEXT: The recent study by Scaglione et al., addresses the issue of IC outpatients with SARS-CoV-2 infection. Authors describe the real-life use of SARS-CoV-2 antivirals and/or monoclonal antibodies and the clinical benefit in high-risk COVID-19 patients. The study supports the use of early combination therapy in a subgroup of extremely high risk patients, and considers the combined strategy as a gold standard regimen to both increase the effectiveness of early treatment, especially in IC individuals, and, reduce the emergence of SARS-CoV-2 escape mutants. CONCLUSION: A tailored and standardised therapeutic approach in case of IC out and inpatients with SARS-CoV-2 infection is needed.
format Online
Article
Text
id pubmed-9742028
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-97420282022-12-12 The unmet need for COVID-19 treatment in immunocompromised patients Alessandra, D’Abramo Serena, Vita Emanuele, Nicastri BMC Infect Dis Correspondence BACKGROUND: Immunocompromised (IC) patients are at increased risk of severe and/or prolonged COVID-19. MAIN TEXT: The recent study by Scaglione et al., addresses the issue of IC outpatients with SARS-CoV-2 infection. Authors describe the real-life use of SARS-CoV-2 antivirals and/or monoclonal antibodies and the clinical benefit in high-risk COVID-19 patients. The study supports the use of early combination therapy in a subgroup of extremely high risk patients, and considers the combined strategy as a gold standard regimen to both increase the effectiveness of early treatment, especially in IC individuals, and, reduce the emergence of SARS-CoV-2 escape mutants. CONCLUSION: A tailored and standardised therapeutic approach in case of IC out and inpatients with SARS-CoV-2 infection is needed. BioMed Central 2022-12-12 /pmc/articles/PMC9742028/ /pubmed/36503419 http://dx.doi.org/10.1186/s12879-022-07918-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Alessandra, D’Abramo
Serena, Vita
Emanuele, Nicastri
The unmet need for COVID-19 treatment in immunocompromised patients
title The unmet need for COVID-19 treatment in immunocompromised patients
title_full The unmet need for COVID-19 treatment in immunocompromised patients
title_fullStr The unmet need for COVID-19 treatment in immunocompromised patients
title_full_unstemmed The unmet need for COVID-19 treatment in immunocompromised patients
title_short The unmet need for COVID-19 treatment in immunocompromised patients
title_sort unmet need for covid-19 treatment in immunocompromised patients
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9742028/
https://www.ncbi.nlm.nih.gov/pubmed/36503419
http://dx.doi.org/10.1186/s12879-022-07918-x
work_keys_str_mv AT alessandradabramo theunmetneedforcovid19treatmentinimmunocompromisedpatients
AT serenavita theunmetneedforcovid19treatmentinimmunocompromisedpatients
AT emanuelenicastri theunmetneedforcovid19treatmentinimmunocompromisedpatients
AT alessandradabramo unmetneedforcovid19treatmentinimmunocompromisedpatients
AT serenavita unmetneedforcovid19treatmentinimmunocompromisedpatients
AT emanuelenicastri unmetneedforcovid19treatmentinimmunocompromisedpatients

Ejemplares similares